Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release In the News Image Library Awards & Recognitions
  1. July 26, 2024

    Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  2. July 19, 2024

    Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  3. June 27, 2024

    Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  4. May 23, 2024

    Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

    Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...

    View more
  5. March 28, 2024

    Harbour BioMed Reports Full Year 2023 Financial Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...

    View more
  6. January 24, 2024

    Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.

    Cambridge, MA, Rotterdam, NL, Suzhou, CN   Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...

    View more
  7. January 19, 2024

    Harbour BioMed Announces Positive Profit Alert

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...

    View more
  8. December 15, 2023

    Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)

    Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...

    View more
  9. August 28, 2023

    Harbour BioMed Announces 2023 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...

    View more
  10. August 28, 2023

    Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— August 28, 2023   Harbour BioMed (the“Company”, HKEX: 02142) announced that the U.S. Foo...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2024 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG